Broes Stefanie, Verbaanderd Ciska, Casteels Minne, Lacombe Denis, Huys Isabelle
Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
Front Med (Lausanne). 2020 Feb 11;7:33. doi: 10.3389/fmed.2020.00033. eCollection 2020.
Today, many initiatives and papers are devoted to clinical trial data (and to a lesser extent sample) sharing. Journal editors, pharmaceutical companies, funding agencies, governmental organizations, regulators, and clinical investigators have been debating the legal, ethical, and social implications of clinical data and sample sharing for several years. However, only little research has been conducted to unveil the patient perspective. To substantiate the current debate, we aimed to explore the attitudes of patients toward the re-use of clinical trial samples and data and to determine how they would prefer to be involved in this process. Sixteen in-depth interviews were conducted with cancer patients currently participating in a clinical trial. This study indicates a general willingness of cancer patients participating in a clinical trial to allow re-use of their clinical trial data and/or samples by the original research team, and a generally open approach to share data and/or samples with other research teams, but some would like to be informed in this case. Despite divergent opinions about how patients prefer to be engaged, ranging from passive donors up to those explicitly wanting more control, participants expressed positive opinions toward technical solutions that allow indicating their preferences. Patients were open to sharing and re-use of data and samples to advance medical research but opinions varied on the level of patient involvement and the need for re-consent. A stratified approach for consent that allows individualization of data and sample sharing preferences may be useful, yet the implementation of such an approach warrants further research.
如今,许多倡议和论文都致力于临床试验数据(以及在较小程度上的样本)共享。期刊编辑、制药公司、资助机构、政府组织、监管机构和临床研究人员就临床数据和样本共享的法律、伦理和社会影响已经辩论了数年。然而,为揭示患者观点所开展的研究却很少。为充实当前的辩论内容,我们旨在探究患者对临床试验样本和数据再利用的态度,并确定他们希望如何参与这一过程。我们对16名正在参与一项临床试验的癌症患者进行了深入访谈。这项研究表明,参与临床试验的癌症患者普遍愿意让原始研究团队再利用他们的临床试验数据和/或样本,并且对于与其他研究团队共享数据和/或样本总体持开放态度,但有些人希望在这种情况下得到通知。尽管对于患者希望如何参与存在不同意见,从被动捐赠者到明确希望有更多控制权的人都有,但参与者对能够表明其偏好的技术解决方案表达了积极看法。患者对于为推进医学研究而共享和再利用数据及样本持开放态度,但在患者参与程度和重新获得同意的必要性方面意见不一。一种允许对数据和样本共享偏好进行个性化设定的分层同意方法可能会有用,但这种方法的实施还有待进一步研究。